Table 4.

Joint-effects survival analysis.

Group	Patients (n=458)	MST (days)	Crude P	Crude HR (95% CI)	Adjusted P*	Adjusted HR* (95% CI)
I	196	3195	0.005	0.655 (0.487-0.881)	0.004	0.645 (0.479-0.867)
II	66	3869	0.075	0.702 (0.476-1.036)	0.071	0.697 (0.470-1.032)
III	196	1910	0.012	Ref.	0.009	Ref.
IV	111	4507	<0001	0.494 (0.334-0.730)	<0.001	0.486 (0.329-0.719)
V	236	2273	0.070	0.751 (0.552-1.023)	0.036	0.718 (0.527-0.979)
VI	111	1487	0.002	Ref.	0.001	Ref.
VII	120	4570	<0.001	0.430 (0.296-0.624)	<0.001	0.428 (0.295-0.622)
VIII	218	2454	0.007	0.660 (0.488-0.893)	0.004	0.643 (0.475-0.871)
IX	120	1478	<0.001	Ref.	<0.001	Ref.
X	98	4570	<0.001	0.048 (0.296-0.678)	<0.001	0.440 (0.290-0.667)
XI	260	2454	0.011	0.671 (0.492-0.914)	0.006	0.645 (0.472-0.881)
XII	100	1446	0.001	Ref.	<0.001	Ref.

Notes: *, adjustment for age and tumor stage. Bold type highlights statistically significant values (P≤0.05).

Abbreviations: PSME, proteasome activator subunit; MST, median survival time; HR, hazard ratio; CI, confidence interval.